Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

NYSEARCA:ATNM - US00507W2061 - Common Stock

1.73 USD
-0.05 (-2.81%)
Last: 9/2/2025, 4:10:03 PM
1.73 USD
0 (0%)
After Hours: 9/2/2025, 4:10:03 PM
Fundamental Rating

2

Taking everything into account, ATNM scores 2 out of 10 in our fundamental rating. ATNM was compared to 542 industry peers in the Biotechnology industry. ATNM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATNM has reported negative net income.
In the past year ATNM has reported a negative cash flow from operations.
In the past 5 years ATNM always reported negative net income.
ATNM had negative operating cash flow in 4 of the past 5 years.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

With a Return On Assets value of -65.12%, ATNM perfoms like the industry average, outperforming 40.77% of the companies in the same industry.
ATNM has a Return On Equity of -215.83%. This is in the lower half of the industry: ATNM underperforms 68.63% of its industry peers.
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATNM has been increased compared to 1 year ago.
Compared to 5 years ago, ATNM has more shares outstanding
ATNM has a better debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.41, we must say that ATNM is in the distress zone and has some risk of bankruptcy.
ATNM has a Altman-Z score of -9.41. This is in the lower half of the industry: ATNM underperforms 71.22% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ATNM is in line with its industry, outperforming 50.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.41
ROIC/WACCN/A
WACC9.86%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
ATNM has a better Current ratio (7.34) than 70.66% of its industry peers.
A Quick Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
ATNM has a better Quick ratio (7.34) than 71.22% of its industry peers.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.82%, which is quite good.
ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)13.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.76% yearly.
Based on estimates for the next years, ATNM will show a very strong growth in Revenue. The Revenue will grow by 267.82% on average per year.
EPS Next Y-7.22%
EPS Next 2Y9.03%
EPS Next 3Y4.85%
EPS Next 5Y12.76%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y267.82%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.03%
EPS Next 3Y4.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATNM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (9/2/2025, 4:10:03 PM)

After market: 1.73 0 (0%)

1.73

-0.05 (-2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-12 2025-11-12
Inst Owners29.95%
Inst Owner Change-34.18%
Ins Owners1.79%
Ins Owner Change-1.12%
Market Cap53.98M
Analysts81.82
Price Target5.1 (194.8%)
Short Float %3.28%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.39%
EPS NQ rev (3m)12.05%
EPS NY rev (1m)-15.75%
EPS NY rev (3m)-15.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.84
P/tB 2.84
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -9.41
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)24.36%
Cap/Depr(5y)31.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
EPS Next Y-7.22%
EPS Next 2Y9.03%
EPS Next 3Y4.85%
EPS Next 5Y12.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y267.82%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.21%
EBIT Next 3Y-10.09%
EBIT Next 5Y-5.07%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A